Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for anti-infective antibody and peptide discovery. Based on our proprietary platform Anti-Bacteria Biomolecular Discovery, we are proud of providing a top-ranking service for discovery of antibody and peptide targeting Haemophilus to clients all around the world.
Haemophilus influenzae is a common member of Haemophilus. It is a human-limited Gram-negative bacterial pathogen that can cause serious infectious diseases including sepsis, meningitis, and pneumonia. Currently a number of antibodies and peptides targeting the surface components of H. influenza have been developed. Naturally acquired antibodies with bactericidal activity have been shown to target the capsular polysaccharide H. influenzae, thereby exerting antibacterial effect. Furthermore, peptides binding to the cell surface of H. influenza, isolated by phage display technology, also show bactericidal potential. There are several important moleculars on the surface of H. influenzae antibody.
CPS is a major virulence factor of H. influenza that protects cell from environmental stress. It is found on the outermost surface of a wide range of the bacteria. Antibodies against the CPS play an important protective role against H. influenzae type b infections.
Lipopolysaccharides (LPS), also known as lipoglycans and endotoxins, are large molecules consisting of a lipid and a polysaccharide composed of O-antigen, outer core and inner core joined by a covalent bond. LPS protects the cell membrane from environmental stress and can induce a strong antibody response in animals.
The OMPs play a role in nutrient uptake, cell adhesion, cell signaling and waste export. Many OMPs, such as outer membrane protein P6 and P2, serve as virulence factors that protect Gram-negative bacteria from a harsh environment. Hence, they are regarded as targets for the development of bactericidal antibodies and vaccines.
Fig. 1 Schematic representation of membrane proteins and outer membrane vesicles of Haemophilus influenzae as novel vaccine targets. (Varela et al. 2012)
Creative Biolabs has years of experience in the therapeutic antibody/peptide discovery, which allows us to provide the comprehensive and high-quality service to facilitate your anti-Haemophilus projects. We have established a powerful AntInfectâ„¢ Platform that offers diverse solutions including antigen-specific B lymphocytes cytometry technology, hybridoma technology and phage display technology for anti-Haemophilus antibody development. Besides, we also establish a diverse phage display library for affinity selecting the peptides binding to the cell surface of Haemophilus. Please free to contact us for more details.
Reference: